FDA-BLA761105
Document details
Summary
SKYRIZI (Risankizumab-rzaa), being an injectable drug approved under the BLA, is likely to be assigned a J-code for Medicare billing. Given its classification as an orphan drug and its high cost, passNew injectable drug approval may affect Medicare billing.
Affected specialty
Dermatology alerts →Source document
http://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761105s000lbl.pdfCLV Intelligence summarizes publicly available federal publications. Not affiliated with or endorsed by any government agency.
Related alerts
4Policy FDA-BLA761262 · Dermatology
SKYRIZI (risankizumab-rzaa) is an injectable drug approved for use under Medicare Part B, likely leading to the assignment of a new J-code for billing purposes. As an orphan drug in the interleukin-23
View alertPolicy FDA-NDA019835 · Dermatology
CETIRIZINE HYDROCHLORIDE, marketed as ZYRTEC HIVES, is an oral drug and will be billed under Medicare Part D. Given that it is not an injectable drug, no J-code will be assigned, and typical reimburse
View alertPolicy FDA-NDA021951 · Dermatology
As ABSORICA (isotretinoin) is an oral drug, it will be billed under Medicare Part D. Given that it is a medication used for severe acne, prescribers should consider any prior authorizations or step th
View alertPolicy FDA-BLA761306 · Dermatology
EBGLYSS (LBRIKIZUMAB-LBKZ) will be billed under Part B as it is an injectable drug. Billing teams should confirm the specifics of the J-code upon the release of the FDA label.
View alert